REGENXBIO Inc
Cerrado
SectorSanidad
9.87 -0.5
Resumen
Variación precio
24h
Mínimo
9.77
Máximo
10.96
Ingresos | -23M -90M |
|---|---|
Ventas | -24M 6.4M |
BPA | -1.72 |
Margen de beneficios | -1,408.588 |
Empleados | 371 |
EBITDA | -14M -77M |
Recomendaciones | Compra Fuerte |
|---|---|
Estimación a 12 Meses | +109.53% upside |
Próximas Ganancias | 6 ago 2026 |
|---|
Capitalización Mercado | -20M 500M |
|---|---|
Apertura anterior | 10.37 |
Cierre anterior | 9.87 |
Noticias sobre sentimiento de mercado
By Acuity
38%
62%
114 / 342 Clasificación en Healthcare
REGENXBIO Inc Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Acerca de REGENXBIO Inc
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.